The case for & against
Bull & Bear analysis
Ginkgo Bioworks, Inc. (NYSE: DNA) is a pioneering biotechnology company specializing in synthetic biology and the automation of biological systems. Positioned as a leader in the emerging autonomous labs market, Ginkgo is transforming research workflows and methodologies by combining advanced automation with innovative lab designs. The company's focus on developing its Nebula system, a highly automated laboratory platform, aims to streamline biotechnological endeavors while reducing operational costs and enhancing efficiency in the industry.
Bull says
- ↑$373M cash, zero bank debt covers projected $125–150M 2026 burn.
- ↑250M annual run-rate cost reduction achieved, improving margins.
- ↑Early Nebula adopters express strong interest in lab automation.
- ↑$29M ARPA-H contract and OpenAI collaboration expand revenue pipeline.
- ↑R&D expense cut 38% to $30M, reflecting disciplined spending.
- ↑Macro tailwinds: rising biotech automation demand and government support.
Bear says
- ↓Q1 2026 revenue fell 49% YoY to $19M; core down 37% ex-divestiture.
- ↓Cash burn remains high: $48M in Q1 and $125M projected for 2026.
- ↓Negative earnings yield and valuation concerns may deter investors.
- ↓Weak institutional interest highlights low confidence in upside.
- ↓Automation tech integration unproven; execution failures could arise.
- ↓Illumina and Thermo Fisher competition may pressure pricing and margins.
Investment themes with DNA
Stocks with high short interest ratios
Stocks with highest short interest
Stocks recommended for short-selling opportunities
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- 2026, our focus will be on investing to win the category of autonomous labs, and I'm really excited, even since we just spoke a few months ago, this category has really been growing in attention.
- I think this is a really nice, as I talked about last time, opportunity both for Ginkgo to keep our focus on the autonomous labs and for the team at Perimeter to grow under their own brand with a new set of defense tech focused investors.
- $373 million with no bank debt as of Q1 2026.
Bear points
- But you know, there's a big motion right now where, uh, we're seeing an increasing amount of drug discovery work moving to China, uh, from Kendall square was talking about earlier here in the Boston area. And that's because simply Chinese scientists are paid a third as much and they're doing equal work to what's happening here in the US.
- Revenue was $19 million in the first quarter of 2026, down 49% compared to the first quarter of 2025.
- Net loss from continuing operations was $76 million in the first quarter of 2026, compared to a loss of $83 million in the prior year period.